CX1739

維基百科,自由的百科全書
跳至導覽 跳至搜尋
CX1739
File:CX1739 structure.png
臨床資料
其他名稱CX-1739
法律規範狀態
法律規範
  • Investigational New Drug
識別資訊
  • N-methyl-N-(oxan-4-yl)-2,1,3-benzoxadiazole-5-carboxamide
CAS號1086377-48-1  checkY
PubChem CID
ChemSpider
UNII
E編碼{{#property:P628}}
CompTox Dashboard (EPA)
  • {{#property:P3117}}Module:EditAtWikidata第29行Lua錯誤:attempt to index field 'wikibase' (a nil value)
ECHA InfoCard{{#property:P2566}}Module:EditAtWikidata第29行Lua錯誤:attempt to index field 'wikibase' (a nil value)
化學資訊
化學式C13H15N3O3
摩爾質量261.28 g·mol−1
3D模型(JSmol
  • CN(C1CCOCC1)C(=O)C2=CC3=NON=C3C=C2
  • InChI=1S/C13H15N3O3/c1-16(10-4-6-18-7-5-10)13(17)9-2-3-11-12(8-9)15-19-14-11/h2-3,8,10H,4-7H2,1H3
  • Key:IRYRMRDDVXULFG-UHFFFAOYSA-N

CX1739是一種由Cortex藥業(現為RespireRx)開發的研究性新藥,目前正在評估其用於治療多種疾病,例如注意力不足過動症[1]自閉症[2]、阿片引發的呼吸抑制[3][4]Module:WikidataLink第216行Lua錯誤:attempt to index field 'wikibase' (a nil value)[5]

合成[編輯]

CX1739可由可由苯並呋咱-5-甲酸和N-甲基四氫吡喃-4-胺反應製得。[6]

參考文獻[編輯]

  1. ^ Radin DP, Lippa A, Rana S, Fuller DD, Smith JL, Cerne R, Witkin JM. Amplification of the therapeutic potential of AMPA receptor potentiators from the nootropic era to today. Pharmacology, Biochemistry, and Behavior. 2025, 248: 173967. PMC 11849398可免費查閱. PMID 39894310. doi:10.1016/j.pbb.2025.173967.  已忽略未知參數|pmc-embargo-date= (幫助)
  2. ^ Silverman J, Oliver C, Karras M, Gastrell P, Crawley J. AMPAKINE enhancement of social interaction in the BTBR mouse model of autism. Neuropharmacology. 2013, 64 (1): 268–282. PMC 3445667可免費查閱. PMID 22801296. doi:10.1016/j.neuropharm.2012.07.013. 
  3. ^ Radin DP, Zhong S, Cerne R, Shoaib M, Witkin JM, Lippa A. Low-Impact Ampakine CX1739 Exerts Pro-Cognitive Effects and Reverses Opiate-Induced Respiratory Depression in Rodents. Future Pharmacology. 2024, 4: 173–187. doi:10.3390/futurepharmacol4010012可免費查閱. 
  4. ^ Xiao D, Xie F, Xu X, Zhou X. The Impact and Mechanism of Ampakine CX1739 on Protection Against Respiratory Depression in Rats. Future Medicinal Chemistry. 2020, 12 (23): 2093–2104. PMID 33030058. doi:10.4155/fmc-2020-0256. 
  5. ^ Ren J, Ding X, Greer JJ. Ampakines Enhance Weak Endogenous Respiratory Drive and Alleviate Apnea in Perinatal Rats. American Journal of Respiratory and Critical Care Medicine. 2015, 191 (6): 704–710. PMID 25594679. doi:10.1164/rccm.201410-1898OC. 
  6. ^ Xiao, Dian; et al. The impact and mechanism of ampakine CX1739 on protection against respiratory depression in rats. Future Medicinal Chemistry (2020), 12(23), 2093-2104. doi:10.4155/fmc-2020-0256.